Alliance Health closes third funding round in just 18 months with Series A exceeding RMB 100M

Following its Pre-A round financing in April of this year, Wuhan Alliance Health Technology Co., Ltd. ("Alliance Health") has recently completed a Series A financing round exceeding 100 million yuan, backed by its innovative business model and sustained profitability.

This round was led by Cenova Capital, a renowned healthcare-focused investment institution in China, with its existing shareholder Sherpa Healthcare Partners making an oversubscribed follow-on investment. Cenova Capital expressed strong confidence in Alliance Health's innovative ecosystem, which embeds low-frequency insurance products into high-frequency health services. By integrating non-medical-insurance payment channels with out-of-hospital healthcare service systems, this model is positioned to create a differentiated and sustainable development pathway amid ongoing healthcare policy reforms and an accelerating aging population trend.

Since its establishment in 2024, Alliance Health has completed three rounds of financing within just one and a half years, with all investments coming from well-known institutions focused on the deep integration of healthcare and insurance sectors. Bolstered by the extensive insurance capital resources of its investors, Alliance Health will further accelerate synergistic development with the insurance industry.

Cenova Capital is one of the earliest healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sectors in China. Since inception in 2010, Cenova now has seven funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.

Sherpa Healthcare Partners was founded in 2018, the founders previously worked together in one of China's leading venture capital firms, built and led its professional medical investment team since 2011, set up the dedicated healthcare investment fund and responsible for healthcare investment. Sherpa has invested in leading companies in many key areas, such as Pharma, GeneTech, MedTech and Medical services. And the team has become one of their earliest and most important investors.